Evolus Inc (EOLS) - Total Assets
Based on the latest financial reports, Evolus Inc (EOLS) holds total assets worth $219.00 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Evolus Inc book value and equity for net asset value and shareholders' equity analysis.
Evolus Inc - Total Assets Trend (2015–2024)
This chart illustrates how Evolus Inc's total assets have evolved over time, based on quarterly financial data.
Evolus Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Evolus Inc's total assets of $219.00 Million consist of 65.1% current assets and 34.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 37.4% |
| Accounts Receivable | $47.68 Million | 20.5% |
| Inventory | $12.16 Million | 5.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $48.75 Million | 21.0% |
| Goodwill | $21.21 Million | 9.1% |
Asset Composition Trend (2015–2024)
This chart illustrates how Evolus Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Evolus Inc stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Evolus Inc's current assets represent 65.1% of total assets in 2024, an increase from 4.9% in 2015.
- Cash Position: Cash and equivalents constituted 37.4% of total assets in 2024, up from 4.9% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 29.0% of total assets, a decrease from 94.0% in 2015.
- Asset Diversification: The largest asset category is intangible assets at 21.0% of total assets.
Evolus Inc Competitors by Total Assets
Key competitors of Evolus Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
|
USA | $5.76 Million |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867
|
China | CN¥8.15 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Guobang Pharma Ltd
SHG:605507
|
China | CN¥10.58 Billion |
Evolus Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.02 | 2.47 | 0.71 |
| Quick Ratio | 1.53 | 2.23 | 0.69 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $68.18 Million | $89.55 Million | $-52.64 Million |
Evolus Inc - Advanced Valuation Insights
This section examines the relationship between Evolus Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 53.71 |
| Latest Market Cap to Assets Ratio | 1.25 |
| Asset Growth Rate (YoY) | 23.1% |
| Total Assets | $232.57 Million |
| Market Capitalization | $291.69 Million USD |
Valuation Analysis
Above Book Valuation: The market values Evolus Inc's assets above their book value (1.25x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Evolus Inc's assets grew by 23.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Evolus Inc (2015–2024)
The table below shows the annual total assets of Evolus Inc from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $232.57 Million | +23.05% |
| 2023-12-31 | $189.00 Million | +6.19% |
| 2022-12-31 | $177.98 Million | -30.88% |
| 2021-12-31 | $257.48 Million | +23.16% |
| 2020-12-31 | $209.07 Million | -13.05% |
| 2019-12-31 | $240.44 Million | +39.92% |
| 2018-12-31 | $171.84 Million | +12.88% |
| 2017-12-31 | $152.23 Million | +96.44% |
| 2016-12-31 | $77.50 Million | -4.68% |
| 2015-12-31 | $81.30 Million | -- |
About Evolus Inc
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels.… Read more